A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: Prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin

Atherosclerosis

Volumn 129, Issue 2, 1997, Pages 231-239

  Nestel, Paul ^a   Simons, Leon ^b   Barter, Phillip ^c   Clifton, Peter ^d   Colquhoun, David ^e   Hamilton Craig, Ian ^f   Sikaris, Ken ^g   Sullivan, David ^h  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d CSIRO   (Australia)

^e WESLEY HOSPITAL   (Australia)

^f REPATRIATION GENERAL HOSPITAL   (Australia)

^g ST VINCENT S HOSPITAL   (Australia)

^h ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

combined hyperlipoproteinemia; gemfibrozil; predictors of response; simvastatin

Indexed keywords

APOLIPOPROTEIN; CHOLESTEROL; GEMFIBROZIL; INSULIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; FEMALE; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; APOLIPOPROTEINS E; CHOLESTEROL; CROSS-OVER STUDIES; DIETARY FATS; GEMFIBROZIL; GENOTYPE; HYPERLIPIDEMIA, FAMILIAL COMBINED; HYPERLIPOPROTEINEMIAS; INSULIN; LIPIDS; LIPOPROTEIN(A); LIPOPROTEINS; LOVASTATIN; PREDICTIVE VALUE OF TESTS; SIMVASTATIN; TRIGLYCERIDES;

EID: 0030895889     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(96)06031-5     Document Type: Article

References (28)

1. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease, II: genetic analysis in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973;52:1544.
2. Grundy SM, Chait A, Brunzell JD. Familial combined hyperlipidemia workshop. Arteriosclerosis 1987;7:203.
3. Taskinen M. Insulin resistance and lipoprotein metabolism. Curr Opin Lipidol 1995;6:153.
4. Genest JJ, Martin-Munley S, McNamara JR et al. Prevalence of familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85:2025.
5. Risk Factor Prevalence Study: Survey No 3 1989, Canberra: National Heart Foundation and Australian Institute of Health, 1990.
6. Franceschini G, Cassinotti M, Vecchio G et al. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler Thromb 1994;14:1569.
7. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993;88:2762.
8. Allain CC, Poon LC, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470.
9. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973;19:476.
10. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1970;11:583.
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of ultracentrifuge. Clin Chem 1972;18:499.
12. Hixson JE, Vernia DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545.
13. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982;23:97.
14. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J 1995;16:5.
15. Dammerman M, Breslow JL. Genetic basis of lipoprotein disorders. Circulation 1995;91:505.
16. Carmena R, Roederer G, Mailloux H, Lussier-Cacan S, Davignon J. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apoliporotein E polymorphism. Metabolism 1993;42:895.
17. Ojala JP, Helve E, Ehnholm C, Aalto-Setala K, Kontula KK, Tikkanen MJ. Effect of apolipoprotein E polymorphism and Xbal polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia. J Int Med 1991;230:397.
18. Sullivan DR, Lam CWK, Jessup W, Dean RT, Hensley WJ. Postprandial changes in apolipoprotein(a) concentration of triglyceride-rich lipoproteins can be reproduced by in vitro incubation: implications for underlying mechanism. Atherosclerosis 1993;103:139.
19. Farnier M, Truong-Tan N, Regy C. Comparative multicentre trial of the efficacy and tolerability of ciprofibrate and simvastatin in the treatment of mixed type IIB hyperlipoproteinaemias. J Drug Dev 1992;5:13.
20. Bruckert E, Dejager S, Chapman MJ. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis 1993;100:91.
21. Yuan J, Tsai MY, Hunninghake DB. Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis 1994;110:1.
22. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993;94:350.
23. Farnier M, Bonnefous F, Debbas N, Irvine A. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch Intern Med 1994;154:441.
24. Arad Y, Ramakrishnan R, Ginsberg HN. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism 1992;41:487.
25. Cabezas MC, de Bruin TWA, Kock LAW et al. Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion. Metabolism 1993;42:497.
26. Simo IE, Yakichuk JA, Ooi TC. Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome. Atherosclerosis 1993;100:55.
27. Nozaki S, Lena Vega G, Haddox RJ, Dolan ET, Grundy SM. Influence of lovastatin on concentrations and composition of lipoprotein subfractions. Atherosclerosis 1990;84:101.
28. Ohrvall M, Lithell H, Johansson J, Vessby B. A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin- dependent diabetes mellitus and hyperlipoproteinemia. Metabolism 1995;44:212.